



Canadian
Cancer Clinical
Trials Network

Réseau canadien
d'essais cliniques
sur le cancer

Canadian Cancer Clinical Trials Network

3CTN Y11Q3 Performance Report

October 1, 2024 – December 31, 2024

Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials 2

 Patient Recruitment at All Network Sites 2

 Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment 3

 Portfolio Trials and Accruals by Region/Site 4

 Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Alberta, British Columbia, and Manitoba 4

 Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba 5

 Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Ontario 6

 Number of active recruiting 3CTN Portfolio trials – Ontario 7

 Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Newfoundland and Quebec..... 8

 Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec..... 9

 Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Pediatric Cancer Centres..... 10

 Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres 11

Section B: 3CTN Portfolio Metrics..... 12

 Active Recruiting Portfolio Trials by Disease Site and Phase 12


 Overview of Portfolio Applications – Process Efficiency..... 13

 Trials Added to the 3CTN Portfolio in Y11Q3 (October 1 – December 31, 2024)..... 14

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 100% within five years.



- Notes:
- 883 patients were recruited (864 to Adult and 19 to Pediatric cancer centres) to Portfolio trials in Quarter 3 bring the Y11 total to 2686.
 - Overall, ~24% of Adult Sites (9 out of 38) are on target to meet or exceeded their Y11 target of 90% above pre-3CTN baseline.
 - *Pediatric progress to pre-3CTN baseline recruitment is shown.

Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment

Objective: To improve trial access and overcome barriers to trial participation for under-represented populations.

Site Name	Primary Site Remote Access Patient	Satellite Site Remote Access Patient	AYA Accrual Aged (15-39)
Waterloo Regional Health Network	0	1	0
Juravinski Cancer Centre	0	0	2
Sunnybrook Health Sciences Centre	0	0	2
Trillium Health Partners - Credit Valley Hospital	0	2	0
CancerCare Manitoba	0	0	2
BC Cancer – Vancouver	0	0	1
BC Cancer – Prince George	0	0	1
Cross Cancer Institute	0	0	1
The Arthur Child Comprehensive Cancer Centre	0	0	1
CancerCare Manitoba - Pediatrics	0	0	1
Centre hospitalier universitaire de Sainte-Justine	1	0	5
Montreal Children's Hospital	0	0	1
BC Children's Hospital	0	0	1
Children's Hospital of Eastern Ontario	0	0	1
IWK Health Centre	2	0	0
McMaster Children's Hospital - Hamilton Health Sciences Centre	1	0	0
Jim Pattison Children's Hospital	1	0	0
Stollery Children's Hospital	0	0	3
The Hospital for Sick Children	2	0	0
Total	7	3	22

*Table excludes remote access patients recruited through the Canadian Remote Access Framework for Clinical Trials (CRAFT) proof of concept project. Numbers based on date of remote access initiation.

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11				
						Q1	Q2	Q3	% of Baseline	% of Target
CancerCare Manitoba	99	44	59	90	58	10	12	9	31%	16%
Western Manitoba Cancer Centre	1	0	1	4	1	0	0	0	0%	0%
Manitoba Total	100	44	60	94	59	10	12	9	31%	16%
BC Cancer – Vancouver	106	154	175	203	148	34	23	30	82%	43%
BC Cancer – Abbotsford	16	1	2	8	7	2	4	4	63%	33%
BC Cancer – Prince George	1	14	21	13	9	3	4	3	1000%	526%
BC Cancer – Kelowna	38	36	35	56	66	12	11	5	74%	39%
BC Cancer – Victoria	26	40	42	35	73	11	19	12	162%	85%
BC Cancer – Surrey	44	0	0	21	27	3	7	7	39%	20%
British Columbia Total	231	245	275	336	330	65	68	61	84%	44%
Cross Cancer Institute	102	202	118	0	65	13	6	13	31%	17%
The Arthur Child Comprehensive Cancer Centre	76	248	166	0	61	10	9	14	43%	23%
Alberta Total	178	450	284	0	126	23	15	27	37%	19%
Western Region Total	509	739	619	430	515	98	95	97	57%	30%

Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2023-24)				Y11 (2024-25)		
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
CancerCare Manitoba	37	17	17	15	15	17	17	16	17	19	14	15	14	14	16	15
Western Manitoba Cancer Centre	0	1	1	2	2	2	2	2	2	2	2	2	2	2	2	0
BC Cancer – Vancouver	50	29	27	29	30	31	40	40	43	44	44	46	35	38	38	36
BC Cancer – Abbotsford	6	0	1	1	2	2	3	2	2	2	2	3	4	3	3	4
BC Cancer – Prince George	2	6	5	5	8	3	4	5	5	5	5	6	10	7	7	10
BC Cancer – Kelowna	23	8	8	8	4	10	10	10	11	11	11	16	17	14	14	13
BC Cancer – Victoria	12	11	8	9	10	11	9	9	9	13	13	15	18	15	15	15
BC Cancer – Surrey	6	-	-	-	-	7	7	7	7	7	6	6	8	5	5	5
Cross Cancer Institute	29	25	22	22	22	-	-	-	-	19	19	32	23	16	16	17
The Arthur Child Comprehensive Cancer Centre	20	23	25	25	22	-	-	-	-	29	27	23	32	21	21	19

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Ontario

Network Site	Pre-3CTN Baseline	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11				
						Q1	Q2	Q3	% of Baseline	% of Target
Verspeeten Family Cancer Centre	186	693	656	506	695	154	153	132	236%	124%
Waterloo Regional Health Network	20	24	23	58	32	1	3	2	30%	16%
Windsor Regional Cancer Centre	14	2	3	2	11	0	2	2	29%	15%
Juravinski Cancer Centre	181	142	190	136	170	39	22	27	49%	26%
Cambridge Memorial Hospital	11	9	11	6	0	0	0	0	0%	0%
St. Joseph's Healthcare Hamilton	21	54	87	56	23	0	0	0	0%	0%
Walker Family Cancer Centre	17	7	23	38	13	3	3	0	35%	19%
Oakville Trafalgar Memorial Hospital	1	-	-	0	0	0	0	0	0%	0%
Sunnybrook Health Sciences Centre	141	395	671	593	708	291	276	298	613%	323%
Humber River Health	1	4	2	14	32	7	5	2	1400%	737%
Michael Garron Hospital	2	0	0	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	267	338	390	488	71	93	96	66%	35%
Markham Stouffville Hospital	1	3	0	6	1	1	3	6	1000%	526%
Mount Sinai Hospital	21	67	543	121	2	1	1	0	10%	5%
Northeast Cancer Centre	24	7	2	5	8	1	0	3	17%	9%
North York General Hospital	1	7	10	21	5	4	4	5	1300%	684%
Royal Victoria Regional Health Centre	8	13	44	37	27	7	1	1	113%	59%
St. Michael's Hospital	19	0	9	1	17	1	3	6	53%	28%
Southlake Regional Health Centre	10	9	13	9	13	2	2	2	60%	32%
Thunder Bay Regional Health Sciences Centre	26	2	39	22	19	6	2	6	54%	28%
Trillium Health Partners - Credit Valley Hospital	27	2	10	12	23	2	12	4	67%	35%
William Osler Health System	1	2	3	6	4	0	3	2	500%	263%
The Ottawa Hospital Cancer Centre	132	483	771	830	570	121	93	98	236%	124%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	59	52	48	37	17	13	15	110%	58%
R.S. McLaughlin Durham Regional Cancer Centre	22	3	7	26	16	14	4	10	127%	67%
Central Region Total	1324	2254	3507	2943	2914	743	698	717	163%	86%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)		
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Verspeeten Family Cancer Centre	79	42	38	39	36	32	29	31	29	30	27	29	46	28	29	26
Waterloo Regional Health Network	11	6	7	7	8	11	11	11	11	10	10	10	12	6	8	10
Windsor Regional Cancer Centre	4	2	2	2	2	8	3	3	3	3	3	4	8	4	4	5
Juravinski Cancer Centre	51	38	31	35	37	36	29	27	27	36	25	21	27	20	20	16
Cambridge Memorial Hospital	5	2	3	3	2	2	2	2	2	2	0	0	0	0	0	2
St. Joseph's Healthcare Hamilton	2	2	2	2	2	2	2	2	2	2	2	2	3	2	2	2
Walker Family Cancer Centre	10	6	6	6	8	8	8	8	7	7	7	7	5	6	6	6
Oakville Trafalgar Memorial Hospital		-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Sunnybrook Health Sciences Centre	10	32	30	35	40	45	48	48	53	50	48	49	41	56	60	62
Humber River Health	0	1	0	2	1	0	1	1	1	1	1	1	3	1	1	2
Michael Garron Hospital	3	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
Princess Margaret Cancer Centre	91	68	68	66	64	73	74	74	75	81	78	81	93	97	97	60
Markham Stouffville Hospital	0	0	0	1	1	2	2	2	2	1	1	2	3	1	1	1
Mount Sinai Hospital	6	3	2	3	3	3	3	3	4	4	4	4	2	4	4	4
Northeast Cancer Centre	10	9	9	9	9	9	9	9	11	10	10	9	6	9	9	11
North York General Hospital	0	4	5	5	5	5	5	5	3	3	1	1	2	2	2	3
Royal Victoria Regional Health Centre	5	12	13	11	11	12	12	12	12	12	11	12	9	14	14	7
St. Michael's Hospital	4	1	1	2	1	1	1	1	1	2	2	2	7	4	4	6
Southlake Regional Health Centre	3	8	7	9	9	9	9	9	9	9	8	8	3	12	12	12
Thunder Bay Regional Health Sciences Centre	8	2	3	4	5	4	4	5	5	4	5	6	7	2	3	3
Trillium Health Partners - Credit Valley Hospital	9	6	6	6	7	7	6	6	6	6	6	6	9	6	6	4
William Osler Health System	0	2	2	1	2	2	2	2	2	2	2	2	2	2	3	4
The Ottawa Hospital Cancer Centre	56	37	43	44	43	39	37	38	38	38	34	33	42	35	35	35
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	21	21	23	24	21	20	20	18	19	18	17	17	20	20	17
R.S. McLaughlin Durham Regional Cancer Centre	13	3	3	4	3	6	8	8	8	8	5	7	14	12	11	11

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11				
						Q1	Q2	Q3	% of Baseline	% of Target
Newfoundland Health Services	15	5	10	17	11	4	4	0	53%	28%
Atlantic Total	15	5	10	17	11	4	4	0	53%	28%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	90	156	127	92	4	7	2	15%	8%
CHU de Québec – Université Laval, adults	180	372	456	198	170	51	55	48	86%	45%
Quebec Total	267	462	612	325	262	55	62	50	63%	33%
Eastern Region Total	282	467	622	342	273	59	66	50	34%	18%

Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)		
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Newfoundland Health Services	6	9	8	8	6	5	5	6	5	5	4	3	7	5	5	5
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	29	28	27	21	21	22	22	22	29	27	27	17	29	30	25
CHU de Québec – Université Laval, adults	39	31	34	31	30	31	30	29	28	32	30	30	28	39	40	45

Patients recruited to 3CTN Portfolio trials, FY2024/25 (Y11) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y7 Total	Y8 Total	Y9 Total	Y10 Total	Y11			
						Q1	Q2	Q3	% of Baseline
BC Children's Hospital	34	30	24	19	16	2	1	1	12%
CancerCare Manitoba - Pediatrics	18	12	6	9	10	2	1	4	39%
Centre hospitalier universitaire de Sainte-Justine	42	51	54	21	24	4	5	4	31%
Children's Hospital - London Health Sciences Centre	12	5	5	14	4	2	0	0	17%
Children's Hospital of Eastern Ontario	20	14	16	16	17	3	1	1	25%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	29	26	18	12	1	0	2	18%
IWK Health Centre	20	6	11	9	8	2	0	1	15%
Janeway Children's Health and Rehabilitation Centre	4	5	2	5	0	1	0	0	25%
Jim Pattison Children's Hospital	6	7	3	4	4	1	0	1	33%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	16	24	16	4	3	1	0	29%
Montreal Children's Hospital	24	16	20	13	6	2	1	1	17%
Stollery Children's Hospital	11	20	23	11	9	1	2	2	45%
The Hospital for Sick Children	91	26	73	43	17	4	4	2	11%
Pediatric Total	313	256	301	198	131	28	16	19	20%


Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)				Y11 (2024-25)		
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
BC Children's Hospital	15	17	17	17	17	18	19	19	19	20	19	20	17	22	22	24
CancerCare Manitoba - Pediatrics	19	14	16	16	20	20	20	21	21	22	22	24	28	21	25	15
Centre hospitalier universitaire de Sainte-Justine	9	22	27	29	27	29	24	22	24	29	24	26	36	26	29	24
Children's Hospital - London Health Sciences Centre	5	16	16	14	18	17	16	16	16	17	16	16	14	8	16	7
Children's Hospital of Eastern Ontario	8	16	14	16	16	17	17	17	22	17	14	13	19	8	13	8
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	21	20	22	23	19	24	23	22	24	21	22	25	16	19	17
IWK Health Centre	9	20	19	21	23	25	25	26	26	30	29	31	25	35	35	38
Janeway Children's Health and Rehabilitation Centre	5	10	13	10	9	10	10	10	10	11	13	11	11	13	13	12
Jim Pattison Children's Hospital	7	8	7	7	8	8	8	8	8	8	8	8	10	11	11	12
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	17	20	20	24	25	25	25	25	25	25	25	14	25	25	25
Montreal Children's Hospital	5	22	24	25	26	27	30	30	27	28	27	24	33	22	23	21
Stollery Children's Hospital	3	14	13	12	13	15	15	15	16	17	16	16	20	22	22	24
The Hospital for Sick Children	13	24	30	27	28	28	27	27	27	29	31	30	34	31	31	29

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN’s impact.



Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	59	63	29	1
2022	36	33	3	0
2023	41	42	12	0
2024	47	47	3	0
2025	7	7	5.6	0

Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed ²	Average FPR Time (days) ³	Median FPR Time (days) ³
2018	10	7	84	77
2019	16	17	112	86
2020	7	6	137	134
2021	9	13	112	108
2022	3	1	44	44
2023	6	7	63	58
2024	2	3	40	36
2025	2	1	39	39

¹ From Portfolio application receipt date to date of approval decision for period beginning Jan 13, 2015.

² Counts are based on the completed reviews in that calendar year. E.g., for an application submitted for review in 2019 but completed in 2020, the FPR will be counted for 2020.

³ FPR process begins on the date the applicant agrees to initiate the FPR process and ends on the date when the final reviewer package is submitted to 3CTN (data based on completed FPRs).

Link: [Portfolio Applications Report](#)

Trials Added to the 3CTN Portfolio in Y11Q3 (October 1 – December 31, 2024)

Trial short title	Trial phase	Disease site	Complexity rating	Trial link
(CHUSJ) MIRV	Phase I/II	Brain/CNS	High	NCT06666348
(COG) ACNS2321	Phase II	Brain/CNS	High	NCT06368817
(PBTC) PBTC-049	Phase I	Brain/CNS	High	NCT03598244
(PBTC) PBTC-059	Phase I	Brain/CNS	Standard	NCT04903080
(UHN) 22-5074 / PRESERVE	Not Applicable	Breast	Standard	NCT05592938
(CCTG) BLC.6 / A032103 / MODERN	Phase II/III	Genito-Urinary	Standard	NCT05987241
(CCTG) PR.25 / OPTION-DDR	Phase III	Genito-Urinary	Standard	NCT06439225
NRG - GU013	Phase III	Genito-Urinary	Standard	NCT05946213
(CCTG) VU.2 / STRIVE	Phase II	Gynecological	Standard	NCT05576831
(GOG) GOG-3043 / ROCC	Not Applicable	Gynecological	Low	NCT04831580
(CCTG) HN.13	Phase III	Head and neck	Standard	NCT06641791
(COG) ARAR2221	Phase II	Head and neck	High	NCT06064097
(CCTG) ALC.8 / MM1YA-S01	Phase II	Hematology	Standard	NCT05554406
(COG) AALL2121	Phase II	Hematology	High	NCT05761171
(COG) ACCL1932	Phase III	Hematology	Low	NCT05711667
NRG-CC009	Phase III	Lung	Standard	NCT04804644
(CCTG) SRC.8	Phase III	Sarcoma	Standard	NCT06422806
(CCTG) ME.17	Phase II	Skin / Melanoma	High	NCT06623461

Link: [3CTN's Portfolio Trial Listing](#)